IB Net Payout Yields Model

Invest like me - only at Covestor.com

2021 Roundtable: Vaccine News - Value

By -

-Today our contributors who specialize in value, dividend, high yield, income, and REITs share their thoughts.

-We will return with Part 2 of the 2021 Outlook Roundtable in early January.

-The Marketplace team wishes to all who celebrate a Merry Christmas!


We end our 2021 Roundtable - Part 1 - Vaccine News series with our contributors who focus on value, dividend, high yield, income, and REIT investing. We asked our authors the following:

Now that vaccines are approved in several countries, a post-COVID reality is in sight. How does this impact the investment horizon in your area of expertise for 2021? Name up to three stocks/ETFs that will outperform as a result.

The answers were compiled as late as Sunday, Dec. 20. As usual, feel free to comment below - we'd love to hear your opinions.

Out Fox The Street by Stone Fox Capital: A vaccine sets up the economic reopen trade for 2021 which includes a lot of the stocks in the Out Fox model. These stocks had solid business models harmed by COVID-19 shutdowns. These stocks haven't recovered to pre-virus levels, yet the business prospects are promising heading into a virus-free world. A primary stock of focus is Yext (YEXT). The search experience cloud company has seen growth stall as enterprises focus on work-from-home solutions and delay implementing new search functions on their own website. The stock trades near multi-month lows despite the potential to return to 20%-plus growth when the economy fully reopens.

A recent addition to the watchlist is Vesper Healthcare Acquisition (VSPR) after the company agreed to a business combination with HydraFacial. The beauty health treatment company has seen revenues slump this year due to closed medical spas around the country, but HydraFacial has seen monthly revenues already rebound close to previous highs. During the slowdown, the company was still able to sell more units setting for a strong recovery in treatments once the economy is fully reopened for beauty treatments.

The SPAC trades just above the IPO and PIPE funding rounds at $10 providing investors the opportunity to buy near where institutions bought shares unlike recent hot IPOs.

The airlines remain the riskiest play with the most upside. An airline like United Airlines (UAL) is still down 50% for the year while the company was cheap prior to virus shutting down travel. At a normalized '22 EPS target of $12+, one can easily envision how the airline stock has plenty of upside when travel surges.

Disclosure: Long YEXT and UAL.

See full article on Seeking Alpha. 

Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

By -
Aurora Cannabis was left out of the major deal making in 2018. The cannabis company updated FQ2 guidance to revenues of $50 to $55 million with a continued focus on pure production growth. The stock is down as the market is becoming less impressed with commodity farming operations due to the prime Oregon example. The stock is below key resistance at $5.40 as medical cannabis patient totals failed to impress. As the end of 2018 came and went,   Aurora Cannabis   ( ACB ) was a notable absentee from the deal making in the cannabis market. Just about all of the other major Canadian cannabis players got large investments or signed up powerful partnerships, but the related stocks didn't generally maintain rallies following the deals. Based on the early legalization data in Canada and Oregon, the best option for Aurora Cannabis might actually be selling production capacity while the Canadian market remains hot. Read the full article on Seeking Alpha.  Disclosure: No
Read more

C3.ai: Out Of Steam (Rating Downgrade)

By -
Image
This idea was discussed in more depth with members of my private investing community, Out Fox The Street.  Learn More »   Update - June 23, 2023 C3.ai has fallen back to earth after the Investor Day meeting. The Deutsche Bank analyst call on the meeting suggests the company still isn't ready to produce actual numbers from the generative AI demand.  C3.ai ( NYSE: AI ) shares  fell more than 8%  on Friday after investment firm Deutsche Bank reiterated its sell rating on the enterprise software company after it held its investor meeting. Analyst Brad Zelnick said the event "left a lot to be desired" as there were  no details on financials, "limited" updates on the company's operations and investors did not really attend the event, despite it being positioned as for them. "While we appreciate the vast opportunity presented by AI, the event did nothing to ease our skepticism on the true differentiation of the company's platform, its traction with custome
Read more

Archer Aviation: Promising Developments

By -
Image
  Update - June 12, 2023 Archer is finally in the midst of a breakout on the positive FAA news.  -The acting administrator of the Federal Aviation Administration, Billy Nolen, is in talks to join Archer Aviation (NYSE:ACHR), per a report from Reuters. -Citing sources familiar with the situation, the report indicates Nolen will depart his current position atop the FAA in the next few weeks and will then look to transition to a role at Archer (ACHR). Archer’s rival Joby Aviation (JOBY) previously appointed former FAA chief Michael Huerta to a position on its board in March. Original article posted on Jan. 19 This idea was discussed in more depth with members of my private investing community, Out Fox The Street.  Learn More »   Archer Aviation Inc. jumped to $3 on the excitement of small insider purchases. The eVTOL manufacturer recently announced several major developments towards FAA certification and production of the Midnight aircraft. Archer Aviation stock is interesting, with a $70
Read more